Cingulate (NASDAQ:CING) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.37) by 10.81 percent. This is a 28.12 percent decrease over losses of $(0.32) per share from the same period last year.
Longeveron Announces Pricing For Rights Offering And Expected Calendar; Rights Offering Priced At A $3.00 Subscription Price Per Share
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as
